Atyr Pharma Inc. (NASDAQ:LIFE) shares saw strong trading volume on Wednesday . 208,660 shares traded hands during trading, an increase of 16% from the previous session’s volume of 179,662 shares.The stock last traded at $2.70 and had previously closed at $2.74.

Several research analysts have recently weighed in on the company. Zacks Investment Research cut Atyr Pharma from a “buy” rating to a “hold” rating in a report on Wednesday. BMO Capital Markets assumed coverage on Atyr Pharma in a report on Monday, April 11th. They issued a “market perform” rating on the stock. Finally, William Blair cut Atyr Pharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 31st. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $23.75.

The firm’s market cap is $63.48 million. The company’s 50-day moving average price is $2.99 and its 200-day moving average price is $4.42.

Atyr Pharma (NASDAQ:LIFE) last issued its earnings results on Wednesday, May 11th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.70) by $0.02. On average, equities analysts anticipate that Atyr Pharma Inc. will post ($2.79) EPS for the current fiscal year.

In related news, insider Grove Matsuoka bought 12,412 shares of the company’s stock in a transaction on Wednesday, May 11th. The stock was bought at an average cost of $3.04 per share, with a total value of $37,732.48. Following the completion of the acquisition, the insider now owns 2,412 shares in the company, valued at approximately $7,332.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Paul Schimmel bought 66,219 shares of the company’s stock in a transaction on Thursday, April 14th. The stock was bought at an average cost of $4.18 per share, with a total value of $276,795.42. Following the completion of the acquisition, the director now owns 53,012 shares of the company’s stock, valued at approximately $221,590.16. The disclosure for this purchase can be found here.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.